A new report from the IQVIA Institute for Human Data Science, 'Global Trends in R&D 2025,' indicates stabilization and improvement in multiple key biopharma R&D metrics during 2024. The life sciences innovation ecosystem continued to evolve and expand, adapting to complex uncertainties.
The report highlights progress in several areas, including funding, clinical trial starts, program productivity, and cycle times. Improvements were also observed in late-stage success rates and clinical productivity, demonstrating meaningful year-on-year advancements in biopharmaceutical R&D.
These positive trends suggest a more efficient clinical development landscape, which is favorable for companies like IQVIA that provide research and development solutions. The effective application of productivity enablers has had a positive impact on the efficiency of clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.